



Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Idarucizumab (Praxbind®)
Indication under review	Specific reversal agent for dabigatran (indicated when rapid reversal of dabigatran's anticoagulant effect are required)
Policy No:	APC 134
Date of Issue:	November 2016
Review Date:	November 2019
Policy Statement: Idarucizumab is recommended as an option for the rapid reversal of the anticoagulant effect of dabigatran.	
Traffic Light Status	Red
Key Points considered: <ul style="list-style-type: none">• Idarucizumab is the first agent to be licensed in the UK that reverses the anticoagulant effect of dabigatran etexilate.• The committee also took note of the NICE Evidence Summary New Medicine document on this agent (ESNM 73).• The committee were also informed that this drug is not excluded from the National Tariff and treatment would only be delivered in a hospital setting.	
References: Nice.org.uk/guidance/esnm73	
Date taken to APC:	2 nd November 2016
Date Ratified by GPMOC on Behalf of the Board:	16 th November 2016